1      One patient died in reSURFACE 2, in the tildrakizumab 100 mg group; the patient had alcoholic ca

2 ssigned, 314 to tildrakizumab 200 mg, 307 to tildrakizumab 100 mg, 156 to placebo, and 313 to etanerc

3 ssigned, 308 to tildrakizumab 200 mg, 309 to tildrakizumab 100 mg, and 155 to placebo.

4 eb response system) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo in reSURFACE 1 (2:2:1),

5 RFACE 1 (2:2:1), or to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg (2:2:

6       INTERPRETATION: In two phase 3 trials, tildrakizumab 200 mg and 100 mg were efficacious compare

7 1090 patients were randomly assigned, 314 to tildrakizumab 200 mg, 307 to tildrakizumab 100 mg, 156 t

8  772 patients were randomly assigned, 308 to tildrakizumab 200 mg, 309 to tildrakizumab 100 mg, and 1

9 nteractive voice and web response system) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo i

10 mg, or placebo in reSURFACE 1 (2:2:1), or to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or

11                             Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL

12                                              Tildrakizumab demonstrated important clinical improvemen

13 r participants re-randomised from placebo to tildrakizumab; etanercept was given twice weekly in part

14 cebo group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo).

15 cebo group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo).

16 cept group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo; p<0.0001 for 200 mg vs

17 cept group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo; p=0.0031 for 200 mg vs

18  brodalumab) and newer IL-23p19 antagonists (tildrakizumab, guselkumab, and risankizumab) underscore

19                                              Tildrakizumab is a high-affinity, humanised, IgG1 kappa

20 id two phase 3 trials to investigate whether tildrakizumab is superior to placebo and etanercept in t

21                                              Tildrakizumab was administered subcutaneously at weeks 0